WAYNE, NJ / ACCESSWIRE / June 29, 2021 / Konica Minolta Healthcare Americas, Inc. announced today an agreement with Mercury Medical as the company’s distributor for ultrasound solutions in the anesthesia market. The agreement builds on Konica Minolta’s recent partnership with Medovate to provide a total solution promoting safer ultrasound-guided regional anesthesia. The agreement, effective immediately, covers the distribution of the SONIMAGE® HS2 Compact Ultrasound System throughout the US.
“With the growing use of and interest in image-guided regional anesthesia, Konica Minolta recognized an opportunity to best serve the needs of providers and healthcare facilities by collaborating with Mercury Medical,” says Eric Sumner, Executive Vice President Ultrasound Sales at Konica Minolta. “Aligning with Mercury Medical provides anesthesiologists and medical centers with a familiar and trusted source for image-guided regional anesthesia solutions. Our companies have a common goal to maximize patient outcomes, and we are excited to partner with Mercury Medical to further enhance patient safety and clinical efficiency with our image-guided regional anesthesia solution.”
“For more than 55 years, Mercury Medical has been dedicated to bringing high-quality, innovative solutions to the surgical, anesthesia and airway management markets,” says John Gargaro, MD, President and CEO at Mercury Medical. “Our agreement with Konica Minolta further extends our dedication to these industries as well as our companies’ shared commitment to delivering exceptional products and services that help make a difference in elevating the quality of patient care. We are delighted to join forces with Konica Minolta to further maximize positive patient outcomes.”
The two companies have already partnered by promoting the HS2 System with Medovate’s SAFIRA™ (SAFer Injection for Regional Anesthesia) for a total solution that enhances patient safety and transforms regional anesthesia into a one-physician procedure by allowing a single anesthesiologist to conduct the entire procedure. There are numerous patient benefits resulting from the use of regional anesthesia, including better post-operative analgesia, decreased opioid consumption and length of stay, early rehabilitation, fewer anesthesia-related side effects and high patient satisfaction compared to general anesthesia1,2.
About Konica Minolta Healthcare Americas, Inc.
Konica Minolta Healthcare is a world-class provider and market leader in medical diagnostic imaging and healthcare information technology. With over 75 years of endless innovation, Konica Minolta is globally recognized as a leader providing cutting-edge technologies and comprehensive support aimed at providing real solutions to meet customer’s needs and helping make better decisions sooner. Konica Minolta Healthcare Americas, Inc., headquartered in Wayne, NJ, is a unit of Konica Minolta, Inc. (TSE:4902). For more information on Konica Minolta Healthcare Americas, Inc., please visit www.konicaminolta.com/medicalusa.
About Mercury Medical
Mercury Medical®, Inc. is dedicated to delivering clinically differentiated critical care technology that saves lives throughout the world. For over 55 years clinicians have relied on Mercury Medical as their resource for quickly responding to clinical needs with solutions that improve patient outcomes effectively. The company provides a legacy of innovative products to critical care areas of neonatal, anesthesia, respiratory and EMS markets in more than 58 countries.
Better decisions, sooner.
CONTACT:
Mary Beth Massat
Massat Media
224.578.2388
www.konicaminolta.com/medicalusa
SOURCE: Mercury Medical
View source version on accesswire.com:
https://www.accesswire.com/653533/Konica-Minolta-Healthcare-Selects-Mercury-Medical-as-Distributor-for-Ultrasound-Solutions-in-Regional-Anesthesia
MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, Dec. 27, 2024 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq:…
NEW YORK, Dec. 27, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence Biomed”…
Proposed merger would add a differentiated Phase 3 TROP2 Antibody-drug Conjugate (ADC) to the combined…
HALF-YEAR FINANCIAL REPORT AS OF JUNE 30, 2024 December 27, 2024, 6.00 p.m. Safe Group announces…
GRANTS, NEW MEXICO, Dec. 27, 2024 (GLOBE NEWSWIRE) -- Bright Green Corporation (OTC: BGXX) (“Bright…
BOSTON, Dec. 27, 2024 /PRNewswire/ -- Judge Baker Children's Center d/b/a The Baker Center for…